Search results for "ONCOLOGIA"

showing 10 items of 386 documents

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

2011

Introduction: To date, orally administered chemotherapy and biologic agents represent a significant percentage of all antineoplastic treatments in several types of cancer, which are most likely to increase in the near future. In this scenario, the issue of adherence and persistence to oral therapy is a key issue since poor compliance to oral antineoplastic treatments may negatively influence patients' clinical outcomes and, in turn, cause an increase in costs, number of hospitalizations and time spent in the hospital. Areas covered: The issue of adherence to new oral chemotherapeutic and/or biologic agents has not been deeply evaluated and data published in medical literature are quite scar…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPoor compliancemedicine.medical_treatmentAdministration OralAntineoplastic AgentsPharmacologySocioeconomic FactorMedication AdherencePersistence (computer science)PersistenceAntineoplastic AgentImmunologic FactorNeoplasmsHumansImmunologic FactorsMedicinePharmacology (medical)Intensive care medicineOral therapyCancerChemotherapybusiness.industryCancerHealth Care CostsGeneral MedicineDrug adherencemedicine.diseaseBiologic AgentsHealth Care CostHospitalizationSocioeconomic FactorsAdherenceNeoplasmbusinessOral chemotherapyHumanMedical literatureExpert Opinion on Drug Safety
researchProduct

VIPoma and PPoma

2015

Gastrinomas are rare tumors of the neuroendocrine system, occurring within the pancreas and duodenum. The annual incidence is estimated at 0.5 per million of the population [1]. Overproduction of gastrin by these tumors produces a sustained increase in gastric acid secretion, leading to clinical manifestations of complicated peptic ulcer disease known as the Zollinger-Ellison syndrome (ZES) [2]. Although most gastrinomas grow slowly, over 60 % are malignant and 25 % show rapid aggressive behavior [3-5]. Most commonly gastrinomas metastasize to regional lymph nodes and the liver, and it is this malignant potential which has become increasingly important since the introduction of effective me…

medicine.medical_specialtySettore MED/06 - Oncologia Medicabusiness.industryMedicine (all)Vasoactive intestinal peptidePlasma levelsmedicine.diseaseMalignancyGastroenterologyIslet cell tumourInternal medicineWatery diarrhoeaMedicinePancreatic polypeptideSecretionHuman medicinebusinessVIPoma
researchProduct

Social disparities, health risk behaviors, and cancer

2013

Background: Overall cancer incidence rates decreased in the most recent time period in both men and women, largely due to improvements in surgical therapeutic approaches (tertiary prevention) and screening programs (secondary prevention), but differences in cancer incidence and survival according to socioeconomic status are documented worldwide. Health risk behaviors, defined as habits or practices that increase an individual’s likelihood of harmful health outcomes, are thought to mediate such inequalities. Discussion: Obesity has been related with increased cancer incidence and mortality due to imbalance of leptin and adiponectin which are connected to activation of PI3K, MAPK, and STAT3 p…

medicine.medical_specialtySettore MED/09 - Medicina InternaInequalitySettore MED/06 - Oncologia Medicamedia_common.quotation_subjectMEDLINERisk-TakingRisk FactorsNeoplasmsmedicineHumansObesityHealth riskSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSocioeconomic statusmedia_commonDiet cancer risk behaviorbusiness.industryIncidence (epidemiology)IncidenceSOCIAL DISPARITIESCancerGeneral Medicinemedicine.diseaseObesityCANCERSurgerySocioeconomic FactorsCANCER; SOCIAL DISPARITIESSurgerybusinessTertiary PreventionResearch Article
researchProduct

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

2018

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July …

medicine.medical_specialtySocio-culturaleHormone-receptor positiveExemestane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerElderlyExemestaneWeight lossInternal medicineAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positive; OncologymedicineEverolimus030212 general & internal medicineStomatitisPneumonitisAdvanced breast cancer; Elderly; Everolimus; Exemestane; Hormone-receptor positiveEverolimusbusiness.industryCancermedicine.diseaseRashEverolimuchemistryOncology030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAAdvanced breast cancermedicine.symptombusinessResearch Papermedicine.drug
researchProduct

Pancoast's syndrome caused by lymph node metastasis from breast cancer.

2018

Pancoast’s syndrome may be the result of neoplastic, inflammatory or infectious disease. We report an unusual case of Pancoast’s syndrome in a patient with metastatic breast cancer. A 54-year-old woman, affected by metastatic breast cancer, presented for severe shoulder pain, paraesthesia and numbness in the right arm. Despite further multiple lines of systemic chemotherapy, she developed a progressive enlargement of retropectoral, supraclavicular and infraclavicular lymph node metastases, which involved brachial plexus, apex of lung and anterior mediastinum. Physical examination revealed severe weakness of proximal muscles of the right arm. Neuropathic pain was managed with pharmacological…

medicine.medical_specialtypain (palliative care)Settore MED/06 - Oncologia MedicaPhysical examinationBreast Neoplasmspain (neurology)03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerFatal OutcomeShoulder PainmedicineHumansPain ManagementBrachial PlexusInfraclavicular Lymph NodeZiconotideLungUnusual Presentation of More Common Disease/Injurymedicine.diagnostic_testperipheral nerve diseasebusiness.industryPancoast SyndromeGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancermedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisNeuropathic painNeuralgiaSettore MED/26 - NeurologiaFemaleRadiologyLymph NodesbusinessBrachial plexus030217 neurology & neurosurgerymedicine.drugBMJ case reports
researchProduct

Creazione di un plug-in per il software open-source di visualizzazione di immagini DICOM OsiriX per lo studio delle variazioni dimensionali e densito…

2014

Presentiamo la nostra esperienza riguardo la progettazione e l'utilizzo di un plug-in per il software open-source di visualizzazione di immagini DICOM (OsiriX 32-bit; GNU General Public License) per la valutazione dei criteri dimensionali e densitometrici di metastasi epatiche in TCMS.

metastasi epaticheoncologiaopen sourceTCMSmetastasiDICOM
researchProduct

“Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients: South…

2008

metastatic colorectal cancercapecitabineSettore MED/06 - Oncologia Medica
researchProduct

Biomarcadores clínico-patológicos y moleculares en cáncer de colon en estadios iniciales: análisis en biopsias líquidas y en tejido tumoral. Implicac…

2017

En España, el CCR es el tercer tumor más prevalente en hombres y el segundo en mujeres, siendo el tumor más prevalente teniendo en cuenta ambos sexos. La detección serológica de autoanticuerpos contra antígenos asociados al tumor ha sido ampliamente estudiada en la búsqueda de potenciales biomarcadores diagnósticos y pronósticos. La baja sensibilidad individual de cada autoanticuerpo hace que no resulten útiles como método diagnóstico del CCR. Hasta el momento, las guías internacionales sólo recomiendan el uso del marcador tumoral CEA en el seguimiento de los pacientes intervenidos, ya que una elevación de su valor en este periodo puede alertar sobre una posible recidiva de la enfermedad. D…

oncologia clinicaoncología clínica
researchProduct

L'oncologia pediatrica

2012

oncologia pediatrica
researchProduct

FITOVIGILANZA: INTERAZIONI FARMACO-FITOTERAPICI IN PAZIENTI ONCOLOGICI ED IMMUNOCOMPROMESSI

2012

oncologiaSettore BIO/14 - FarmacologiaFITOVIGILANZA
researchProduct